Hregen

Connect with us:
Connect with us:
Connect with us:
Connect with us:
Work with Us

Initiated Phase 1 clinical trial in 10 patients to assess both safety and clinical efficacy. First two sites, Mayo Clinic and Univ of Michigan, have been activated in July and August of 2023 to recruit patients.

FDA’s approval of  HRGN’s first IND is an extremely important milestone for HRGN as it will transition Biostage into a clinical stage company

About Us
Regenerations Ahead
Leadership            Board of directors              Scientific & Clinical advisory board
HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.
About Us
Regenerations Ahead
Leadership             Board of directors                Scientific & Clinical advisory board
HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Subscription to Newsletter

Sign up for trending updates on Medical Industry.